---
title: "Outlook Therapeutics, Inc. (OTLK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OTLK.US.md"
symbol: "OTLK.US"
name: "Outlook Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T22:35:35.347Z"
locales:
  - [en](https://longbridge.com/en/quote/OTLK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OTLK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OTLK.US.md)
---

# Outlook Therapeutics, Inc. (OTLK.US)

## Company Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [outlooktherapeutics.com](https://outlooktherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:14.000Z

**Overall: D (0.70)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 269 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -388.61% |  |
| P/B Ratio | -5.09 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 147453167.44 |  |
| Revenue | 333141.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 198.37% | A |
| Profit Margin | -18297.50% | E |
| Gross Margin | -17.18% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -388.61% | E |
| Total Assets YoY | 14.77% | B |
| Net Assets YoY | 10.68% | B |
| Cash Flow Margin | 77.18% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.02 | E |
| Gearing Ratio | 232.44% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Outlook Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-388.61%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-5.09",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "147453167.44",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "333141.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "198.37%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-18297.50%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-17.18%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-388.61%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.77%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.68%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "77.18%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "232.44%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.42 | 272/390 | 4.22 | 3.96 | 3.55 |
| PB | -5.09 | 515/390 | - | - | - |
| PS (TTM) | 442.61 | 282/390 | 141.34 | 60.79 | 28.74 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-10T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Hold | 2 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.22 |
| Highest Target | 6.00 |
| Lowest Target | 0.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OTLK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OTLK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OTLK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OTLK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**